However, within the TME, they promote cancer progression by inhibiting anti‐tumour responses through IL‐2 secretion which modulates NK cells, impairing function, or directly by inhibiting antigen presenting cells (APCs) resulting in blockade of cytokines secretion and hence T cell activation [37]. The gene discussed is IL2; the disease is neoplasm.